Invention Grant
- Patent Title: Isoindoline-1-one derivatives as cholinergic muscarinic M1 receptor positive alloesteric modulator activity for the treatment of Alzheimers disease
-
Application No.: US15830634Application Date: 2017-12-04
-
Publication No.: US10457670B2Publication Date: 2019-10-29
- Inventor: Masami Yamada , Shinkichi Suzuki , Takahiro Sugimoto , Minoru Nakamura , Hiroki Sakamoto , Makoto Kamata
- Applicant: Takeda Pharmaceutical Company Limited
- Applicant Address: JP Osaka
- Assignee: Takeda Pharmaceutical Company Limited
- Current Assignee: Takeda Pharmaceutical Company Limited
- Current Assignee Address: JP Osaka
- Agency: Hamre, Schumann, Mueller & Larson, P.C.
- Priority: JP2014-089585 20140423
- Main IPC: C07D405/14
- IPC: C07D405/14 ; C07D405/04 ; C07D209/46 ; C07D401/06 ; C07D401/10 ; C07D401/14 ; C07D403/04 ; A61K31/145 ; A61K31/325 ; A61K31/4035 ; A61K31/4155 ; A61K31/4406 ; A61K31/4439 ; A61K31/445 ; A61K31/55 ; C07D471/04 ; C07D403/10 ; A61K31/13 ; A61K31/045
Abstract:
The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like.The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the specification, or a salt thereof.
Public/Granted literature
Information query
